ABVC - Thai ethics committee approves ABVC's phase 2 study protocol for its eye-gel substitute
- ABVC BioPharma ( NASDAQ: ABVC ) on Thursday said that it had got approval from a Thai ethics committee for its phase 2 clinical study protocol for its medical device Vitargus.
- The study protocol was approved by the Central Research Ethics Committee of the National Research Council of Thailand.
- ABVC's Vitargus is a substitute for the vitreous humor in the eye, which is the gel-like fluid that fills the eye cavity.
- ABVC said it had selected the Thailand, Ramathibodi Hospital, Mahidol University located in Bangkok and Srinagarind Hospital, Khon Kaen University located in Khon Kaen Province to initiate the study.
- Despite the news, ABVC stock has lost 10.5% to $0.94 in premarket trading. It closed 10.9% higher at $1.05 on Wednesday.
For further details see:
Thai ethics committee approves ABVC's phase 2 study protocol for its eye-gel substitute